Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats

Journal of Hypertension

Volumn 24, Issue 1, 2006, Pages 103-108

  Hirano, Tsutomu ^a   Ran, Jianmin ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 1 receptor; Angiotensin II type 2 receptor; Cholesterol; Rats

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CHOLESTEROL; FRUCTOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; OLMESARTAN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HYPERCHOLESTEROLEMIA; INFUSION; INTRAHEPATIC CHOLESTASIS; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 29144486186     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000198030.30095.98     Document Type: Article

References (21)

1. Julius S. Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension. J Cardiovasc Pharmacol 1990; 15 (suppl 5):S53-S58.
2. Rao RH. Pressor dose of angiotensin II increase hepatic glucose output and decrease insulin sensitivity in rats. J Endocrinol 1996; 148:311-318.
3. Ogihara T, Asano T, Ando K, Ogihara T, Asano T, Ando K, et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002; 40:872-879.
4. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30:487-496.
5. Ran J, Hirano T, Adachi M. Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab 2004; 287:E955-E961.
6. Ran J, Hirano T, Adachi M. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. J Hypertens 2005; 23:1525-1530.
7. Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 2004; 27:293-299.
8. Giacchetti G, Sechi LA, Griffin CA, Don BR, Mantero F, Schambelan M. The tissue renin-angiotensin system in rats with fructose-induced hypertension: overexpression of type 1 angiotensin II receptor in adipose tissue. J Hypertens 2000; 18:695-702.
9. Lako-Futo Z, Szokodi I, Sarman B, Foldes G, Tokola H, Ilves M, et al. Evidence for a functional role of angiotensin II type 2 receptor in the cardiac hypertrophic process in vivo in the rat heart. Circulation 2003; 108:2414-2422.
10. Li JS, Touyz RM, Schiffrin EL. Effects of AT1 and AT2 angiotensin receptors antagonists in angiotensin-infused rats. Hypertension 1998; 31:487-492.
11. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98:418-425.
12. Macari D, Whitebread S, Cumin F, De Gasparo M, Levens N. Renal actions of the angiotensin AT2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. Eur J Pharmacol 1994; 259:27-36.
13. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Med Sci 1959; 37:911-917.
14. Keidar S, Attias J, Heinrich R, Coleman R, Aviram M. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis 1999; 146:249-257.
15. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287:E227-E232.
16. Nashar K, Nguyen JP, Jesri A, Morrow JD, Egan BM. Angiotensin receptor blockade improves arterial distensibility and reduces exercise-induced pressor responses in obese hypertensive patients with the metabolic syndrome. Am J Hypertens 2004; 17:477-482.
17. Kristianson K, Fyhrquist F, Devereux RB, Kjeldsen SE, Lindholm LH, Lyle PA, et al. An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. Clin Ther 2003; 25:1186-1199.
18. Rajagopalan S, Brook R, Mehta RH, Supiano M, Pitt B. Effect of losartan in aging-related endothelial impairment. Am J Cardiol 2002; 89:562-566.
19. Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, et al., RENAAL Study. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26:1402-1407.
20. Derosa G, Cicero AF, Bertone G, Piccinni MN, Fogari E, Ciccarelli L, Fogari R. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther 2004; 26:1228-1236.
21. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27:457-464.